New Research Uncovers the Role of T Cells in Atrial Fibrillation

Medical News: Atrial fibrillation (AF) is a common heart rhythm disorder that affects millions of people worldwide. This condition, if left untreated, can lead to severe complications such as stroke and heart failure. While much has been known about how electrical issues in the heart contribute to AF, recent research is shedding light on the surprising role that the body’s immune system, particularly T cells, plays in this condition. This Medical News report aims to explore the findings from this research and what it could mean for future treatments.


Overview of pathogenesis of Atrial Fibrillation.
Decreasing ICa,L and SERCA2a along with increasing CaMKII, NCX (Na+/Ca2+-exchanger) and RyR2 expression and phosphorylation result in DADs, known as Ca2+ handling abnormities. Trigger is from Ca2+ handling abnormities. Ion channel dysfunctions including decreasing INa and Ito, increasing IKur and IK1, decreasing and misdistribution of connexin-40 and connexin-43 cause electrical remodeling, known as decreasing ERP. Structural remodeling is due to necrosis and apoptosis of cardiomyocytes and cardiac fibrosis. Both electrical and structural remodeling can induce reentry. Trigger and reentry promote AF occurrence.

The Immune System and the Heart
It has long been understood that AF results from irregular electrical signals in the heart that disrupt its ability to beat in a coordinated way. What is now becoming clearer is that immune cells, especially T cells, may also have a hand in this process. T cells, a key component of the body's adaptive immune system, help to protect the body from infections and abnormal cells. However, when something goes wrong, these same cells can cause inflammation and damage to the heart tissue.
 
The study, which involved researchers from the Union Hospital, Tongji Medical College at Huazhong University of Science and Technology-China, examined how different subsets of T cells are linked to AF. This article delves into their roles and how their activity correlates with AF progression.
 
T Cell Subsets and Their Roles in AF
Several types of T cells have been identified as playing important roles in the development and worsening of AF. The researchers found that AF patients had elevated levels of certain T cells in their blood and heart tissue. These T cells are not just passive bystanders; they actively contribute to the electrical and structural changes in the heart that lead to AF. Here are the main types of T cells involved:
 
-CD4+CD28null T Cells
One of the most intriguing findings from the study is the role of CD4+CD28null T cells, a type of immune cell that is typically associated with inflammation and autoimmune diseases. These cells are unique because they lack the CD28 molecule, which makes them more resistant to signals that would usually control their activity. As a result, they can become aggressive and cause more harm to tissue s, including the heart.
 
In AF patients, CD4+CD28null T cells were found to release inflammatory molecules like TNF-α and IFN-γ, which directly affect the heart's cells. These inflammatory signals can disrupt calcium balance in the heart muscle cells, leading to abnormal heartbeats. Additionally, the study noted that these T cells release perforin, a protein that allows toxic enzymes to enter heart muscle cells and induce cell death. This cellular damage contributes to the structural remodeling of the heart, which is a key feature of AF.
 
-Th17 Cells and Treg Cells
Th17 cells and Treg cells are two other subsets of T cells that play contrasting roles in the immune system. Th17 cells promote inflammation, while Treg cells help suppress it. The balance between these two types of cells is crucial for maintaining heart health. In AF patients, the researchers found that there was an increase in Th17 cells and a decrease in Treg cells, creating an environment ripe for inflammation and fibrosis (the formation of excess fibrous tissue in the heart).
Fibrosis stiffens the heart tissue, making it harder for the heart to pump effectively and increasing the likelihood of AF. The elevated levels of IL-17, a cytokine produced by Th17 cells, were linked to increased inflammation and fibrosis in AF patients, further emphasizing the role of this immune imbalance.
 
-CD8+ T Cells and Their Role in AF
The study also highlighted the involvement of CD8+ T cells, which are known for their ability to kill infected or abnormal cells. In AF patients, CD8+ T cells were found in higher numbers, particularly in areas of the heart that had undergone fibrotic changes. These cells release cytotoxic proteins like perforin and granzymes, which can kill heart muscle cells and disrupt their electrical activity. This cell death and subsequent fibrosis contribute to the structural changes that make AF more likely.
 
Interestingly, CD8+ T cells were found to be especially prevalent in patients with more severe forms of AF, suggesting that they play a role in the progression of the disease from intermittent episodes to chronic, persistent AF.
 
Inflammation, Fibrosis, and AF
Inflammation is a well-known contributor to AF, and the study reinforces this connection by showing how T cells drive the inflammatory processes that damage the heart. The inflammatory signals released by T cells not only disrupt the electrical signals in the heart but also promote fibrosis, which stiffens the heart and makes AF more difficult to treat.
 
Potential New Treatments
The findings from this study suggest that targeting T cells and their inflammatory signals could offer a new approach to treating AF. For example, drugs that block the activity of CD4+CD28null T cells or reduce the levels of IL-17 could help reduce the inflammation and fibrosis that drive AF. Additionally, therapies that boost the number of Treg cells could help restore the balance of the immune system and prevent the harmful effects of Th17 cells.
 
The researchers also pointed out that more studies are needed to fully understand how T cells contribute to AF and to develop effective treatments. However, the potential for new therapies that target the immune system is promising, especially for patients who do not respond well to current AF treatments like anti-arrhythmic drugs or catheter ablation.
 
Conclusion
This study offers new insights into the role of the immune system in AF, highlighting the importance of T cells in driving both inflammation and structural changes in the heart. CD4+CD28null T cells, Th17 cells, and CD8+ T cells all contribute to the progression of AF by promoting inflammation, cell death, and fibrosis. By better understanding these immune processes, researchers hope to develop new treatments that target the root causes of AF rather than just managing its symptoms.
 
The study findings were published in the peer-reviewed journal: NPJ Cardiovascular Health.
https://www.nature.com/articles/s44325-024-00026-6
 
For the latest on Atrial Fibrillation, keep on logging to Thailand Medical News.
 
Read Also:
https://www.thailandmedical.news/news/covid-19-news-israeli-study-finds-that-sars-cov-2-infections-can-trigger-new-onset-atrial-fibrillation
 
https://www.thailandmedical.news/news/john-hopkins-proposes-new-echocardiogram-diagnostics-that-can-identify-covid-19-patients-that-are-at-risk-of-developing-atrial-fibrillation
 
https://www.thailandmedical.news/news/new-study-reveals-effective-treatment-for-recent-onset-atrial-fibrillation